Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

Ann Hematol. 2018 May;97(5):905-907. doi: 10.1007/s00277-018-3233-9. Epub 2018 Jan 11.

Authors

Marcel Nijland¹, Tom van Meerten², Annika Seitz³, Gerwin Huls², Robby Kibbelaar⁴, Lydia Visser³, Anke van den Berg³, Arjan Diepstra³

Affiliations

¹ Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. [email protected].
² Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
³ Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
⁴ Department of Pathology, Pathology Friesland, Leeuwarden, the Netherlands.

PMID: 29327077
DOI: 10.1007/s00277-018-3233-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brentuximab Vedotin
Cisplatin / administration & dosage
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Cytarabine / administration & dosage
Dexamethasone / administration & dosage
Doxorubicin / administration & dosage
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunoconjugates / therapeutic use
Janus Kinase 1 / antagonists & inhibitors*
Janus Kinase 2 / antagonists & inhibitors*
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / immunology
Lymphoma, B-Cell / radiotherapy
Lymphoma, B-Cell / therapy
Mediastinal Neoplasms / drug therapy*
Mediastinal Neoplasms / immunology
Molecular Targeted Therapy*
Neoplasm Proteins / antagonists & inhibitors*
Nitriles
Prednisone / administration & dosage
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyrimidines
Radiotherapy, Adjuvant
Remission Induction
Rituximab / administration & dosage
Salvage Therapy*
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immunoconjugates
Neoplasm Proteins
Nitriles
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Cytarabine
Rituximab
Vincristine
Dexamethasone
Brentuximab Vedotin
Doxorubicin
ruxolitinib
Cyclophosphamide
pembrolizumab
JAK1 protein, human
JAK2 protein, human
Janus Kinase 1
Janus Kinase 2
Cisplatin
Prednisone

Supplementary concepts

CHOP protocol
DHAP protocol